Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
Date:11/15/2011

CRANBURY, N.J., Nov. 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2011. Palatin reported a net loss of $3.4 million, or $(0.10) per basic and diluted share, for the quarter ended September 30, 2011, compared to a net loss of $4.6 million, or $(0.39) per basic and diluted share, for the same period in 2010.

The decrease in net loss for the quarter ended September 30, 2011, compared to the same period last fiscal year, is the result of Palatin's previously announced strategic decision to reduce staffing levels and to focus resources and efforts on clinical trials of bremelanotide and preclinical development of an inhaled formula of PL-3994 and a new peptide drug candidate for sexual dysfunction.  The decrease in net loss per share was also significantly impacted by the higher number of shares outstanding in the quarter ended September 30, 2011 compared to the same period last fiscal year due primarily to the sale of shares of stock in March 2011.

REVENUERevenues for the quarter ended September 30, 2011 were $27,000, compared to $216,000 for the same period in 2010, reflecting the decrease in revenue recognized under Palatin's agreements with AstraZeneca AB.

COSTS AND EXPENSESTotal operating expenses for the quarter ended September 30, 2011 were $3.4 million, compared to $4.8 million for the comparable quarter of 2010. The decrease in operating expenses for the quarter is the result of Palatin's previously announced strategic decision to reduce staffing levels and to focus resources and efforts on clinical trials of bremelanotide and PL-3994 and preclinical development of an inhaled formul
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Second generation biofuels are a viable solution to ... as natural gas is very cheap, this is affecting the ... valuable as they could be in comparison to natural gas. ... made it difficult for renewable energy developers to get the ... For these reasons, certain companies have shifted their focused within ...
(Date:7/29/2014)... , July 29, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, applauds the ... taking a strong position in opposition to current ... 27, 2014 publication.  The New York Times also ... this week exploring the issue called "High Time:  ...
(Date:7/29/2014)... Tenn. (PRWEB) July 29, 2014 ... in biomass feedstock supply innovation and supply chain ... proprietary feedstock management systems, Energy Grangeā„¢ and Supply ... of R&D and in-the-field testing aimed at consolidating ... offering benefits to landowners, farmers and feedstock end ...
(Date:7/29/2014)... 29, 2014 G-CON Manufacturing Inc., the ... today announced a new leadership appointment designed to drive ... and abroad. , Maik Jornitz, Chief Operating Officer ... President charged with leading the pioneering company through its ... this stage of development and look forward to providing ...
Breaking Biology Technology:Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2
... Consortium With Broad ... Portfolio of IV Products, ... BAX ) announced today that Novation, the University HealthSystem,Consortium,s (UHC) ... behalf of UHC valued at over $200 million over the,contract ...
... (Pink Sheets: BIEL), announced today that the ... sale by its,distributor, Endotherapeutics Party Limited. ... professionals of,Endotherapeutics will successfully launch ActiPatch in ... of experience in the,medical devices market and ...
... to Identify Pathways and ... to Metabolomic Data, REDWOOD CITY, Calif., Oct. ... solutions to help life science researchers,generate insights from ... solution within Ingenuity,Pathways Analysis to help researchers understand ...
Cached Biology Technology:Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products 2Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products 3Australian Therapeutics Goods Administration Approval for ActiPatch Achieved 2Ingenuity Systems Launches New Metabolomics Solution Within IPA 2
(Date:7/29/2014)... has received from the National Institutes of Health ... project to support the further development of 23andMe,s ... , Specifically, the grant supports four areas ... to improve the company,s ability to identify novel ... to support the collection of a broader set ...
(Date:7/29/2014)... 1 in 100,000 people characterized by a loss of ... unknown, a new study by a team of researchers at ... and other European institutions confirms for the first time that ... July in Nature Genetics , is an important step ... sphincter in the lower esophagus opens, allowing food to enter ...
(Date:7/28/2014)... of two additional coral communities showing signs of damage from ... the 2010 spill in the Gulf of Mexico. The discovery ... of biology at Penn State University. A paper describing this ... the Gulf of Mexico will be published during the last ... the journal Proceedings of the National Academy of Sciences ...
Breaking Biology News(10 mins):23andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 3Mysterious esophagus disease is autoimmune after all 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2
... of the potential health effects associated with accidental exposure ... , The study, "An Analysis of Uranium Dispersal and ... by Sandia scientist Al Marshall, employs analytical capabilities used ... risks associated with uranium handling. , U.S. and British ...
... Cornell University researchers have revealed a process that has ... derived from vitamin A enters a cell's nucleus, where ... basic transport mechanism opens a new door for future ... for the fight against cancer and other diseases. , ...
... HIV is so difficult to contain and treat is its ... to that evolution is vital. , Host cells produce two ... ability to replicate. But HIV produces a protein, called Vif, ... full of variation, both in sequence and in function, according ...
Cached Biology News:Sandia completes depleted uranium study 2Study shows how retinoic acid enters a cell's nucleus 2Study shows how retinoic acid enters a cell's nucleus 3
Request Info...
Prepared in distilled water....
... white. The extinction coefficient , E(1%) at ... phosphate-buffered saline, pH 7.4, containing ... 50% glycerol. Avidin (from egg white) is conjugated ... molecular sieving and is completely ...
NM522 contains an F episome, which is required for production of ssDNA and for blue/white color selection. To maintain the F, NM522 should be grown on minimal (M-9) medium....
Biology Products: